NWBO News and Press, Northwest Biotherapeutics Inc. From 02/17/22

Northwest Biotherapeutics (OTCQB:NWBO +7.6%) began production of its first dendritic cell cancer vaccine for a compassionate use patient at its production facility in Sawston, U.K. The company said the milestone follows approval by the U.K. Medicines and Healthcare Products Regulatory Ag...

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility PR Newswire BETHESDA, Md. , Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ...

Check These 3 Penny Stocks Out For Your List in February After a wild day of trading penny stocks and blue chips, investors continue to search for the best stocks to buy. Now, while the trading day started off strong, it quickly devolved into another day of losses across the board. This...

Are These 3 Penny Stocks Worth Watching Right Now If you’re looking for the best penny stocks to buy, there are hundreds to choose from. As a result of the sheer number of penny stocks out there, finding the best ones for your watchlist is all about understanding where to loo...

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility PR Newswire BETHESDA, Md. , Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax &#x...

NWBO still has not announced toppling data, or TLD. This situation has been ongoing for more than a year after data lock. I will continue to hold, but will not add to my small position. For further details see: Northwest Biotherapeutics: No TLD Yet

Northwest Biotherapeutics (OTCQB:NWBO +12.3%) has closed on $15M financing, which brings the company's cash reserves above $20M. The financing is in the form of a 22-month loan which requires no payments for 8 months, and then provides for a subsequent 14-month amortization period. Interest r...

Northwest Biotherapeutics Announces $15 Million Financing PR Newswire BETHESDA, Md. , Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tum...

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility PR Newswire BETHESDA, Md. , Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ...

This is a recap of DCVax-L's pedigree. Stock is down 25% since my last neutral article. I am celebrating NWBO's one-year data lock anniversary with a buy. For further details see: Northwest Bio: Nowhere To Go But Up